CLIN CHEM LAB MED:比较两种ELISA试剂盒快速检测阿达木单抗血清水平的新方法

2020-01-31 MedSci MedSci原创

因为一些研究显示了药物水平和粘膜愈合之间的相关性.

因为一些研究显示了药物水平和粘膜愈合之间的相关性,阿达木单抗(ADA)在炎性肠病(IBDs)中的治疗药物监测(TDM)已引起越来越多的关注。常规使用酶联免疫吸附法(ELISA)检测血清ADA浓度的局限性促使了快速方法的发展,如QB。我们评估了QB方法与两种已建立的ELISA试剂盒,Promonitor (PM)Lisa-Tracker (LT)的互换性和一致性。

本研究包括50IBD患者的样本。采用重复测量的方差分析、德明回归和布兰-阿尔特曼图进行定量分析。通过根据亚治疗(<5<7.5μg/ mL)和超治疗(> 12μg/ mL)范围的建议临界水平将患者分类为治疗窗口来评估临床意义。

研究结果显示,QB法与两种ELISA试剂盒比较差异有统计学意义,QBQB高估ADA血清值。方法之间缺乏互换性,随着ADA水平的增加,差异也越来越大。ADA值低于9μg/ mLn = 25)的样本子集的分析表明,QB满足了与LT分析可互换的标准。 QB vs. LT的患者分类为ADA治疗窗口的一致性好于QB vs. PM,这三种方法中亚治疗水平的一致性较高(> 75%)。

虽然快速法和ELISA试剂盒在数量上存在差异,影响了它们的互换性,但在鉴别ADA亚治疗价值患者方面的一致性很高。

原始出处:

Emilio J. Laserna-MendietaSara Salvador-MartínComparison of a new rapid method for the determination of adalimumab serum levels with two established ELISA kits

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1991084, encodeId=7e0d19910842d, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Dec 08 05:54:00 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026237, encodeId=2ea1202623e8c, content=<a href='/topic/show?id=ca938941222' target=_blank style='color:#2F92EE;'>#血清水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89412, encryptionId=ca938941222, topicName=血清水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Fri Apr 03 19:54:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903394, encodeId=3804190339450, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sat Nov 07 14:54:00 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610211, encodeId=ff50161021192, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Feb 02 14:54:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615640, encodeId=a94016156404e, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97945, encryptionId=3eb39e945b2, topicName=阿达木)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3dba19658752, createdName=1179102698_36768932, createdTime=Sun Feb 02 14:54:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378764, encodeId=d1f23e876478, content=学习了很有用不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sat Feb 01 00:52:18 CST 2020, time=2020-02-01, status=1, ipAttribution=)]
    2020-12-08 tastas
  2. [GetPortalCommentsPageByObjectIdResponse(id=1991084, encodeId=7e0d19910842d, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Dec 08 05:54:00 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026237, encodeId=2ea1202623e8c, content=<a href='/topic/show?id=ca938941222' target=_blank style='color:#2F92EE;'>#血清水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89412, encryptionId=ca938941222, topicName=血清水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Fri Apr 03 19:54:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903394, encodeId=3804190339450, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sat Nov 07 14:54:00 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610211, encodeId=ff50161021192, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Feb 02 14:54:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615640, encodeId=a94016156404e, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97945, encryptionId=3eb39e945b2, topicName=阿达木)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3dba19658752, createdName=1179102698_36768932, createdTime=Sun Feb 02 14:54:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378764, encodeId=d1f23e876478, content=学习了很有用不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sat Feb 01 00:52:18 CST 2020, time=2020-02-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1991084, encodeId=7e0d19910842d, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Dec 08 05:54:00 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026237, encodeId=2ea1202623e8c, content=<a href='/topic/show?id=ca938941222' target=_blank style='color:#2F92EE;'>#血清水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89412, encryptionId=ca938941222, topicName=血清水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Fri Apr 03 19:54:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903394, encodeId=3804190339450, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sat Nov 07 14:54:00 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610211, encodeId=ff50161021192, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Feb 02 14:54:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615640, encodeId=a94016156404e, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97945, encryptionId=3eb39e945b2, topicName=阿达木)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3dba19658752, createdName=1179102698_36768932, createdTime=Sun Feb 02 14:54:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378764, encodeId=d1f23e876478, content=学习了很有用不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sat Feb 01 00:52:18 CST 2020, time=2020-02-01, status=1, ipAttribution=)]
    2020-11-07 kord1982
  4. [GetPortalCommentsPageByObjectIdResponse(id=1991084, encodeId=7e0d19910842d, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Dec 08 05:54:00 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026237, encodeId=2ea1202623e8c, content=<a href='/topic/show?id=ca938941222' target=_blank style='color:#2F92EE;'>#血清水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89412, encryptionId=ca938941222, topicName=血清水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Fri Apr 03 19:54:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903394, encodeId=3804190339450, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sat Nov 07 14:54:00 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610211, encodeId=ff50161021192, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Feb 02 14:54:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615640, encodeId=a94016156404e, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97945, encryptionId=3eb39e945b2, topicName=阿达木)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3dba19658752, createdName=1179102698_36768932, createdTime=Sun Feb 02 14:54:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378764, encodeId=d1f23e876478, content=学习了很有用不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sat Feb 01 00:52:18 CST 2020, time=2020-02-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1991084, encodeId=7e0d19910842d, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Dec 08 05:54:00 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026237, encodeId=2ea1202623e8c, content=<a href='/topic/show?id=ca938941222' target=_blank style='color:#2F92EE;'>#血清水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89412, encryptionId=ca938941222, topicName=血清水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Fri Apr 03 19:54:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903394, encodeId=3804190339450, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sat Nov 07 14:54:00 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610211, encodeId=ff50161021192, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Feb 02 14:54:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615640, encodeId=a94016156404e, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97945, encryptionId=3eb39e945b2, topicName=阿达木)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3dba19658752, createdName=1179102698_36768932, createdTime=Sun Feb 02 14:54:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378764, encodeId=d1f23e876478, content=学习了很有用不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sat Feb 01 00:52:18 CST 2020, time=2020-02-01, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1991084, encodeId=7e0d19910842d, content=<a href='/topic/show?id=69bd91e371a' target=_blank style='color:#2F92EE;'>#试剂盒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91737, encryptionId=69bd91e371a, topicName=试剂盒)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Dec 08 05:54:00 CST 2020, time=2020-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026237, encodeId=2ea1202623e8c, content=<a href='/topic/show?id=ca938941222' target=_blank style='color:#2F92EE;'>#血清水平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89412, encryptionId=ca938941222, topicName=血清水平)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Fri Apr 03 19:54:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903394, encodeId=3804190339450, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sat Nov 07 14:54:00 CST 2020, time=2020-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610211, encodeId=ff50161021192, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Feb 02 14:54:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615640, encodeId=a94016156404e, content=<a href='/topic/show?id=3eb39e945b2' target=_blank style='color:#2F92EE;'>#阿达木#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97945, encryptionId=3eb39e945b2, topicName=阿达木)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3dba19658752, createdName=1179102698_36768932, createdTime=Sun Feb 02 14:54:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378764, encodeId=d1f23e876478, content=学习了很有用不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sat Feb 01 00:52:18 CST 2020, time=2020-02-01, status=1, ipAttribution=)]
    2020-02-01 飛歌

    学习了很有用不錯

    0

相关资讯

Sci Adv:关于单抗耐药问题,又一关键机制被找到,并有希望逆转耐药性!

导 读:单克隆抗体药物靶向性强、毒性低,具有传统的化学疗法无可比拟的优势。过去的20年,单抗药物在癌症、自身免疫等疾病的治疗领域发挥了重要的作用,然而其治疗效果也同样受到耐药性的困扰。

英国NICE批准BMS的肾癌免疫治疗组合:PD-1 单抗Opdivo和CTLA-4 单抗Yervoy

英国国家健康和护理卓越研究所(NICE)已发布最终评估决定(FAD),批准将免疫检查点抑制剂组合:PD-1 单抗Opdivo(nivolumab)和CTLA-4 单抗Yervoy(ipilimumab),联合使用治疗中度和低风险晚期肾细胞癌(RCC)。

单抗联合化疗新辅助治疗食管鳞癌

食管癌是我国常见的消化系统恶性肿瘤之一,在我国恶性肿瘤中发病率居第5位,死亡率居第4位。目前,手术是食管癌的主要根治性手段之一,在早期阶段外科手术治疗可以达到根治的目的,在中晚期阶段,通过以手术为主的综合治疗(包括术前新辅助和术后辅助治疗)可以使其中一部分患者达到根治,其他患者生命得以延长。免疫治疗的问世,使食管癌的治疗增添了新的选择。2019 ASCO 会议上发布了PD-1联合化疗用于食管癌新辅

单抗界的板蓝根?继HIV、乳腺癌后 leronlimab向NASH发起挑战!

CytoDyn是一家专注于开发新型人源化CCR5单克隆抗体leronlimab(PRO140)用于多种治疗适应症的生物技术公司。近日,该公司宣布与克利夫兰诊所的Daniel Lindne博士达成合作协议,在人源化小鼠模型中检测leronlimab预防非酒精性脂肪性肝炎(NASH)的能力。之前,辉瑞的一款HIV药物maraviroc在非酒精性脂肪性肝病(NAFLD)小鼠模型中已显示出可改善肝脏脂肪变

单抗联合化疗治疗复发转移性膀胱尿路上皮癌患者获益明确

膀胱癌是泌尿系统的常见恶性肿瘤之一,近年来免疫治疗在膀胱癌中取得了重大进展,目前美国FDA已经批准5个PD-1/PD-L1抑制剂用于铂类治疗后进展的晚期膀胱癌。同时,帕博利珠单抗还获批用于局部晚期或转移性尿路上皮癌的一线治疗,由此可见免疫检查点抑制剂在晚期膀胱尿路上皮癌的治疗中愈发重要。同时最新消息显示,Atezolizumab联合化疗一线治疗尿路上皮癌的Ⅲ期IMvigor130研究也达到了无进展

《新英格兰医学杂志》发表针对溃疡性结肠炎的首项头对头临床研究,强调了维多珠单抗与阿达木单抗相比的优越性

日本武田制药有限公司宣布了VARSITY研究的进一步结果,该研究证明了肠道选择性维多珠单抗(Entyvio)与抗肿瘤坏死因子α(抗TNFα)阿达木单抗(Humira)的优越性,目前该单抗在中度至重度活动溃疡性结肠炎(UC)患者中已经实现临床的主要终点,数据发表在《新英格兰医学杂志》(NEJM)上。在第52周时,维多珠单抗31.3%(n = 120/383)的临床缓解率要好于阿达木单抗的22.5%(